| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
126.99(M) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5663 - $7.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
53,676 |
| Total Buy Value |
$0 |
$0 |
$0 |
$460,539 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
15,916 |
259,287 |
288,665 |
818,456 |
| Total Sell Value |
$9,232 |
$437,565 |
$559,901 |
$6,534,439 |
| Total People Sold |
2 |
6 |
8 |
11 |
| Total Sell Transactions |
2 |
7 |
11 |
27 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sarissa Capital Management Lp |
|
– – • |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
24,193 |
235,962 |
|
- |
|
| Sarissa Capital Management Lp |
|
– – • |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
211,769 |
|
- |
|
| Duane Jon R |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
190,339 |
|
- |
|
| Currie Mark G |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
613,419 |
|
- |
|
| Dreyfus Andrew |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
228,313 |
|
- |
|
| Moukheibir Catherine |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
117,944 |
|
- |
|
| Shepard Jay |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
171,555 |
|
- |
|
| Kessler Marla L |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
165,883 |
|
- |
|
| Mchugh Julie |
|
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
208,839 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
540,000 |
1,687,281 |
|
- |
|
| Gaskins Tammi L |
Chief Commercial Officer |
• – – |
2025-05-16 |
4 |
S |
$0.58 |
$1,487 |
D/D |
(2,563) |
242,596 |
|
-28% |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2025-05-16 |
4 |
S |
$0.58 |
$7,745 |
D/D |
(13,353) |
1,147,281 |
|
-28% |
|
| Sarissa Capital Management Lp |
|
– – • |
2025-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,416 |
166,769 |
|
- |
|
| Gaskins Tammi L |
Chief Commercial Officer |
• – – |
2025-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
245,159 |
|
-51% |
|
| Martini Gregory S. |
Chief Financial Officer |
• – – |
2025-02-10 |
4 |
S |
$1.76 |
$21,212 |
D/D |
(12,052) |
183,810 |
|
60% |
|
| Silver Ronald |
Principal Accounting Officer |
• – – |
2025-02-10 |
4 |
S |
$1.76 |
$21,204 |
D/D |
(12,048) |
279,655 |
|
60% |
|
| John Minardo |
Chief Legal Officer |
• – – |
2025-02-10 |
4 |
S |
$1.76 |
$68,531 |
D/D |
(38,938) |
408,132 |
|
60% |
|
| John Minardo |
Chief Legal Officer |
• – – |
2025-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
122,222 |
447,070 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2025-02-10 |
4 |
S |
$1.76 |
$244,753 |
D/D |
(139,064) |
1,160,634 |
|
60% |
|
| Shetzline Michael |
SVP, CMO, Head-Res&Drug |
• – – |
2025-02-10 |
4 |
S |
$1.76 |
$72,633 |
D/D |
(41,269) |
554,007 |
|
60% |
|
| Shetzline Michael |
SVP, CMO, Head-Res&Drug |
• – – |
2025-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
133,333 |
595,276 |
|
- |
|
| Martini Gregory S. |
Chief Financial Officer |
• – – |
2025-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
84,751 |
|
-85% |
|
| Martini Gregory S. |
Chief Financial Officer |
• – – |
2025-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
111,111 |
195,862 |
|
- |
|
| Silver Ronald |
Principal Accounting Officer |
• – – |
2025-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
133,333 |
291,703 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
147,354 |
1,299,698 |
|
- |
|
540 Records found
|
|
Page 1 of 22 |
|
|
0.05 (6.08%) 
